Precision radiation takes on liver cancer: could SABR beat standard care?
NCT ID NCT07628751
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a precise radiation technique called SABR against standard treatments (like heat probes or chemo injections) for early-stage liver cancer. About 218 adults with a single tumor up to 8 cm will be randomly assigned to SABR or standard care. The main goal is to see if SABR better prevents the cancer from growing back in the treated area over two years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Stereotactic Ablative Body Radiotherapy (SABR)
- What this could lead to
- If SABR works better, it could become a new standard, non-invasive treatment option for early liver cancer, potentially improving local control and survival.
- What could go wrong
- This is a Phase 2 trial with 218 participants, so results are still early. SABR may not prove superior to standard care, and side effects from radiation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 218 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Apr 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1\) Histological or radiological diagnosis of single, new HCC with largest diameter =8 cm (BCLC stage 0 or A). * a) If prior history of HCC, the prior HCC must have been: * Early stage, solitary HCC, =5 cm in size and, * Have arisen within a different liver segment to the current HCC and, * Treated with curative intent therapy \>2 years prior with no evidence of active disease at the site. * 2\) As per local multidisciplinary HCC meeting consensus patient is suitable for percutaneous thermal ablation and/or transarterial therapies and not suitable for or declined liver resection and not planned for liver transplantation. * 3\) Child-Pugh score =B7\* with no or diuretic-controlled ascites * 4\) ECOG performance status =2 * 5\) Platelets =50x109/L, Haemoglobin =80 g/L, Neutrophils =1.0x109/L, INR \<1.8 (except if on therapeutic anticoagulation) * 6\) 18 years of age or older and able to provide written consent Exclusion Criteria: * 1\) Presence of multifocal HCC, macrovascular invasion or extrahepatic disease * 2\) Prior treatment for any HCC within last 2 years. * 3\) Clinically evident ascites or hepatic encephalopathy * 4\) Prior abdominal radiation therapy that would preclude the delivery of protocol defined SABR to the tumour. * 5\) Untreated Hepatitis B or C * 6\) Known additional invasive malignancy (excluding non-melanoma skin cancer) that is progressing or required treatment within the last 2 years. * 7\) Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Early hepatocellular carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Trans Tasman Radiation Oncology Group
RECRUITINGWaratah, Australia
-
University Health Network - Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada